Cytosorbents FY2028 EPS Forecast Lowered by HC Wainwright

Cytosorbents Corporation (NASDAQ:CTSO) – Equities research analysts at HC Wainwright dropped their FY2028 earnings estimates for Cytosorbents in a report issued on Thursday, March 26th. HC Wainwright analyst S. Lee now anticipates that the medical research company will post earnings of ($0.04) per share for the year, down from their previous estimate of ($0.03). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents’ FY2029 earnings at ($0.02) EPS.

Other equities research analysts also recently issued research reports about the company. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a report on Thursday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a report on Friday, January 9th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $5.38.

Cytosorbents Price Performance

CTSO stock opened at $0.59 on Monday. The stock’s 50 day simple moving average is $0.69 and its 200 day simple moving average is $0.75. The company has a market cap of $37.24 million, a P/E ratio of -4.56 and a beta of 1.36. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.71 and a current ratio of 2.11. Cytosorbents has a fifty-two week low of $0.50 and a fifty-two week high of $1.39.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Wednesday, March 25th. The medical research company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.04). Cytosorbents had a negative net margin of 22.12% and a negative return on equity of 131.86%. The firm had revenue of $9.23 million during the quarter, compared to analyst estimates of $9.22 million.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Citadel Advisors LLC grew its position in Cytosorbents by 127.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after purchasing an additional 36,790 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after buying an additional 37,519 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Cytosorbents during the 3rd quarter worth approximately $105,000. CIBC Bancorp USA Inc. purchased a new position in shares of Cytosorbents in the 3rd quarter worth approximately $161,000. Finally, CM Management LLC boosted its stake in shares of Cytosorbents by 14.6% in the 4th quarter. CM Management LLC now owns 1,476,500 shares of the medical research company’s stock worth $944,000 after buying an additional 188,372 shares during the last quarter. 32.87% of the stock is owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.